Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Maxim Group Downgrades Inovio Pharmaceuticals (INO) to Hold
-
Inovio Pharmaceuticals (INO) PT Raised to $24 at Maxim Group, Following $71M DoD Contract
-
Pre-Open Stock Movers 03/03: (MITO) (INO) (WIFI) Higher; (CODX) (TLRY) (KPTI) Lower (more...)
-
Inovio Pharmaceuticals (INO) Presents Positive dBiTE Data At AACR - Maxim
-
Pre-Open Stock Movers 03/26: (ALDX) (BBBY) (BIOC) Higher; (CCL) (MYOK) (RCL) Lower (more...)
-
Inovio Pharmaceuticals Completes Sale of Additional Convertible Senior Notes
-
Inovio Pharmaceuticals (INO) PT Lowered to $8 at Maxim Group
-
Inovio Pharma (INO): Promising Prostate Cancer Data - Maxim
-
Inovio Pharma (INO) Prices 12.5M Shares at $6
-
Inovio Announces Pricing of Public Offering of Common Stock
-
Pre-Open Stock Movers 07/19: (AEZS) (VRTX) (SNI) Higher; (DRYS) (NTRS) (HDP) Lower (more...)
-
UPDATE: Inovio Pharmaceuticals (INO) PT Raised to $12 at Maxim Group; 'A Step Closer to HIV Vaccine, PENNVAX-GP Demonstrates High Immune Response Rates'
-
Maxim Group Upgrades Inovio Pharmaceuticals (INO) to Buy
-
Notable Analyst Rating Changes 8/9: (HL) (VALE) (DISH) Upgraded; (PACD) (INO) (WM) Downgraded
-
Maxim Group Downgrades Inovio Pharmaceuticals (INO) to Hold
-
Prima BioMed (PBMD) Immunotherapy Delivery Method Looks Promising - Maxim Group
-
Streetinsider.com's Hot Lunchtime Reads 6/20: (GPRO) (SQ) (INO) (MSFT)
-
Maxim Group Reiterates Bullish View on Inovio (INO) as Zika Vaccine Gets Green Light For Human Study
-
Maxim Group Reiterates Bullish View on Inovio (INO) as Zika Vaccine Moves Closer to Human Trials
-
Inovio (INO) Bullish Stance Reiterated at Maxim Group Amid MERS Trial Patient Recruitment and Zika Vaccine Progress
-
Inovio (INO) PT Lowered to $14 at Maxim Group; 'Buy' Maintained
-
Maxim Lifts PT on Inovio (INO) to $23 Following Initiation of Dosing in PENNVAX-GP Phase 1
-
Inovio Pharma (INO) Closes 9.5M Common Offering for Net Proceeds of $82M
-
Inovio Pharmaceuticals Closes $87.4 Million Underwritten Financing
-
Inovio Pharmaceuticals Closes $87.4 Million Underwritten Financing
-
Inovio Pharma (INO) Prices 9.5M Common Offering at $8/Share
-
Inovio Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Maxim Positive on Inovio Pharmaceuticals (INO) Following Hepatitis B Trial Initiation
-
Maxim Group Comments on Inovio Pharmaceuticals (INO) Ahead of 'Binary Event'
-
Inovio Pharmaceuticals (INO) Posts Q1 Results with Data Ahead - Maxim Group
-
Inovio Pharmaceuticals (INO) Price Target Lifted to $6 at Maxim Group
-
Inovio Pharma (INO) Closes 21.8M Common Stock Offering
-
Pre-Open Stock Movers 9/24: (GWAY) (FU) (AMAT) Higher; (RHT) (ABR) (ETRM) Lower (more...)
-
Inovio Pharmaceuticals (INO) Prices Offering of Common Stock and Warrants
-
Maxim Group Starts Inovio Pharmaceuticals (INO) at Buy

